The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.
19 year old male's three month results from using a combination of Minoxidil, finasteride and dermarolling for hair loss. It was suggested that adding Minoxidil could help with further progress.
The conversation is about using a product containing dutasteride and tamsulosin for hair loss. Users discuss separating the components and potential side effects like frequent urination and changes in libido.
The user asks about the order and compatibility of using topical minoxidil, stemoxydine, The Ordinary natural moisturizing factors + HA for scalp, RU58841, and Nioxin system 2 leave-in treatment. They seek advice on layering these hair loss treatments.
Unused Minoxidil tablets should be disposed of at a pharmacy with take-back services or according to packaging instructions. It's not recommended to give them to others due to legal and safety concerns.
The user is using oral minoxidil, ghk-cu, and HGH for hair regrowth, noticing small vellus hairs on the crown. They avoid traditional DHT blockers like finasteride due to side effects, despite skepticism from others about the effectiveness of ghk-cu.
The conversation discusses an 8.5-month progress of using Minoxidil, Finasteride, and RU58841 for hair loss. People are complimenting the user on the significant improvement in hair thickness.
The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.
A 22-year-old male shared his 4-month progress using topical minoxidil, topical finasteride, dermarolling, ketoconazole shampoo, and supplements for hair loss, showing significant improvement. Users discussed his potential for further recovery, shared purchasing tips for finasteride, and mentioned possible side effects like reduced libido.
The user is exploring hair loss treatments and is interested in procyanidin B2 and annurca apples but has concerns about the effectiveness and availability of supplements. They cannot use Dutasteride or Finasteride and are considering Minoxidil with microneedling.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
A 21-year-old shares their one-year progress using finasteride for hair loss, experiencing initial shedding but eventual regrowth, especially on the crown. They consider switching to dutasteride due to continued hair loss at the front temple and mid-scalp areas.
Switching generic finasteride manufacturers can reduce side effects while maintaining effectiveness. Different fillers in generics may affect bioavailability and cause varying side effects.
Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.
A 22-year-old male is using Dutasteride, Minoxidil, RU58841, and Microneedling to treat hair loss and is wondering if he can regrow hair at his temples. Commenters suggest that he should continue the treatment as it takes time, with full results expected in 2-2.5 years.
A product called HairMDL includes Minoxidil, Dutasteride, Latanoprost, caffeine, Tretinoin, and Triamcinolone. Users are curious about its effectiveness and safety, particularly regarding the topical steroid Triamcinolone.
User used sublingual minoxidil for 5 months and saw progress. Also used topical dutasteride, alfatradiol, tretinoin, and reduced oral finasteride dose.
The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.
The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.
The user shared progress pictures after using topical minoxidil for 8 months and topical finasteride for 5 months, along with other treatments like tretinoin cream, microneedling, and specialized shampoos. They are seeking feedback on their hair regrowth progress and are concerned about reaching a plateau.
The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
The acne medication Winlevi, which contains Clascoterone, is available in the U.S. and may slow down hair loss until a higher concentration treatment, Breezula, is released.
A user is seeking advice on making a topical bicalutamide solution as an alternative to RU58841 for hair loss, while already using dutasteride and minoxidil. They are considering crushing bicalutamide pills and adding them to their minoxidil.
The user shared progress on hair regrowth using oral dutasteride, oral minoxidil, and verteporfin procedures. They reported some regrowth after 6-9 months of treatment.
The user is experiencing hair thinning on the sides and back of the head while the top remains thick. A reply suggests it might be retrograde alopecia.
The user is pleased with increased hair density and thickness after six months of using topical minoxidil and finasteride. They plan to continue the treatment and consider adding dermarolling for potentially better results.
A 24-year-old male with diffuse thinning has been using finasteride for two years, dutasteride for 6-7 months, and oral minoxidil for 5 months, along with topical treatments. He plans to continue this regimen and reassess in August 2026, hoping to stabilize hair loss without surgery.